» Articles » PMID: 19150316

Parenchymal Extinction: Coagulation and Hepatic Fibrogenesis

Overview
Journal Clin Liver Dis
Specialty Gastroenterology
Date 2009 Jan 20
PMID 19150316
Citations 23
Authors
Affiliations
Soon will be listed here.
Abstract

Observations that hepatic inflammation and cirrhosis are associated with the presence of thrombi within the hepatic microvasculature and fibrin-fibrinogen deposition have led to epidemiologic studies showing that carriage of the factor V Leiden mutation, protein C deficiency, and increased expression of factor VIII are associated with rapid progression to cirrhosis in a chronic hepatitis C virus. Additional data suggest that this process may extend more broadly to progression in many forms of chronic liver disease. This article discusses the evidence for a role for coagulation cascade activity in hepatic fibrogenesis and explores the proposed pathogenic mechanisms including the downstream events of thrombin activation. Interference with either the generation of thrombin or its downstream activity may reduce hepatic fibrosis. Also examined are the implications for future therapeutic intervention.

Citing Articles

Platelet, Antiplatelet Therapy and Metabolic Dysfunction-Associated Steatotic Liver Disease: A Narrative Review.

Boccatonda A, Del Cane L, Marola L, DArdes D, Lessiani G, Di Gregorio N Life (Basel). 2024; 14(4).

PMID: 38672744 PMC: 11051088. DOI: 10.3390/life14040473.


Pre-transplant portal vein thrombosis in non-alcoholic fatty liver disease patients-pathogenesis, risk factors, and implications on management.

DeLeeuw P, Agbim U Transl Gastroenterol Hepatol. 2022; 7:27.

PMID: 35892050 PMC: 9257532. DOI: 10.21037/tgh-19-361.


Coagulation and Endothelial Dysfunction Associated with NAFLD: Current Status and Therapeutic Implications.

Ogresta D, Mrzljak A, Cigrovski Berkovic M, Bilic-Curcic I, Stojsavljevic-Shapeski S, Virovic-Jukic L J Clin Transl Hepatol. 2022; 10(2):339-355.

PMID: 35528987 PMC: 9039716. DOI: 10.14218/JCTH.2021.00268.


Hypercoagulability in Patients with Non-Alcoholic Fatty Liver Disease (NAFLD): Causes and Consequences.

Tripodi A, Lombardi R, Primignani M, La Mura V, Peyvandi F, Fracanzani A Biomedicines. 2022; 10(2).

PMID: 35203457 PMC: 8869363. DOI: 10.3390/biomedicines10020249.


The hemostatic and thrombotic complications of liver disease.

McMurry H, Jou J, Shatzel J Eur J Haematol. 2021; 107(4):383-392.

PMID: 34258797 PMC: 9009189. DOI: 10.1111/ejh.13688.